Impedimed Ltd Asset Resilience Ratio
Impedimed Ltd asset resilience ratio. Impedimed Ltd (IPD) has an Asset Resilience Ratio of 46.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Impedimed Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Impedimed Ltd (2007–2025)
Asset resilience ratio of Impedimed Ltd from 2007 to 2025. This chart shows how Impedimed Ltd's Asset Resilience Ratio has changed over time. Read debt load of Impedimed Ltd for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Impedimed Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Impedimed Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$17.71 Million | 46.15% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$17.71 Million | 46.15% |
Asset Resilience Insights
- Very High Liquidity: Impedimed Ltd maintains exceptional liquid asset reserves at 46.15% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Impedimed Ltd Industry Peers by Asset Resilience Ratio
Compare Impedimed Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
BMC Medical Co. Ltd. A
SHE:301367 |
Medical Devices | 44.96% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Hironic Co. Ltd
KQ:149980 |
Medical Devices | 17.42% |
|
DRGEM Corporation
KQ:263690 |
Medical Devices | 2.12% |
|
Oncosil Medical Ltd
AU:OSL |
Medical Devices | 0.00% |
|
Adherium Ltd
AU:ADR |
Medical Devices | 15.45% |
Impedimed Ltd Asset Resilience Ratio by Year (2007–2025)
Impedimed Ltd asset resilience ratio by year from 2007 to 2025. The table below shows the annual Asset Resilience Ratio data for Impedimed Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 52.04% | AU$21.68 Million ≈ $15.34 Million |
AU$41.66 Million ≈ $29.48 Million |
+12.90pp |
| 2024-06-30 | 39.14% | AU$18.39 Million ≈ $13.01 Million |
AU$46.99 Million ≈ $33.25 Million |
+19.42pp |
| 2023-06-30 | 19.71% | AU$13.55 Million ≈ $9.59 Million |
AU$68.74 Million ≈ $48.64 Million |
-33.59pp |
| 2022-06-30 | 53.30% | AU$31.29 Million ≈ $22.14 Million |
AU$58.70 Million ≈ $41.53 Million |
+19.68pp |
| 2021-06-30 | 33.62% | AU$11.50 Million ≈ $8.14 Million |
AU$34.20 Million ≈ $24.20 Million |
+7.07pp |
| 2020-06-30 | 26.55% | AU$8.78 Million ≈ $6.21 Million |
AU$33.06 Million ≈ $23.39 Million |
-9.61pp |
| 2019-06-30 | 36.16% | AU$8.16 Million ≈ $5.78 Million |
AU$22.58 Million ≈ $15.98 Million |
-31.92pp |
| 2018-06-30 | 68.08% | AU$28.30 Million ≈ $20.02 Million |
AU$41.57 Million ≈ $29.41 Million |
-5.30pp |
| 2017-06-30 | 73.38% | AU$47.22 Million ≈ $33.41 Million |
AU$64.34 Million ≈ $45.53 Million |
-- |
| 2016-06-30 | 0.00% | AU$0.00 ≈ $0.00 |
AU$90.57 Million ≈ $64.08 Million |
-- |
| 2012-06-30 | 0.16% | AU$31.00K ≈ $21.93K |
AU$19.61 Million ≈ $13.88 Million |
+0.02pp |
| 2011-06-30 | 0.14% | AU$31.00K ≈ $21.93K |
AU$22.80 Million ≈ $16.14 Million |
-0.08pp |
| 2008-06-30 | 0.21% | AU$31.00K ≈ $21.93K |
AU$14.52 Million ≈ $10.27 Million |
-0.47pp |
| 2007-06-30 | 0.68% | AU$148.00K ≈ $104.72K |
AU$21.79 Million ≈ $15.42 Million |
-- |
About Impedimed Ltd
ImpediMed Limited, a medical technology company, engages in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services in Australia, Europe, North America, and internationally. The company offers SOZO Digital Health Platform which transforms fluid status and tissue composition into insights with a single scan; L-Dex Analysis for Lymphedema, designed fo… Read more